KM-001 is under clinical development by Kamari Pharma and currently in Phase I for Pachyonychia Congenita (Pachyonychia). According to GlobalData, Phase I drugs for Pachyonychia Congenita (Pachyonychia) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the KM-001 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KM-001 overview

KM-001 is under development for the treatment of itch associated with moderate to severe pruritus in patients with lichen simplex chronicus (LSC), type I punctate palmoplantar keratoderma or pachyonychia congenital, severe palmoplantar keratoderma (Olmsted) and ichthyoses (Harlequin ichthyosis). It is administered through topical and oral routes. It acts by targeting transient receptor potential cation channel 3 (TRPV 3).

Kamari Pharma overview

Kamari Pharma is a biopharmaceutical company. The company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3. The company had various major products for skin treatment such as lichen simplex chronicus, and KM 001. Kamari Pharma is headquartered in Herzliya, Tel Aviv, Israel.

For a complete picture of KM-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.